Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (21-30 of 168) with videos related to

Pageof 17
Sort By:
The Journal of Organic Chemistry|January 18, 2005
Synthesis, chromatographic separation, vibrational circular dichroism spectroscopy, and ab initio DFT studies of chiral thiepane tetraol derivativesVanda Cerè, Francesca Peri, Salvatore Pollicino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung CancerGerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2015
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profilingSai-Hong Ignatius Ou, Zachary R Chalmers, Michele C Azada, et al.
Oncoimmunology|February 6, 2018
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapiesAaron M Goodman, Shumei Kato, Philip R Cohen, et al.
Molecular Cancer Therapeutics|August 25, 2017
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M Goodman, Shumei Kato, Lyudmila Bazhenova, et al.
Journal of Natural Products|August 2, 2007
Prismatomerin, a new iridoid from Prismatomeris tetrandra. Structure elucidation, determination of absolute configuration, and cytotoxicityKarsten Krohn, Dietmar Gehle, Sujit Kumar Dey, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Journal of the National Cancer Institute|November 14, 2015
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibVictor Wong, Dean Pavlick, Tim Brennan, et al.
Pageof 17

Showing results (21-30 of 168) with videos related to

Sort By:
Pageof 17
The Journal of Organic Chemistry|January 18, 2005
Synthesis, chromatographic separation, vibrational circular dichroism spectroscopy, and ab initio DFT studies of chiral thiepane tetraol derivativesVanda Cerè, Francesca Peri, Salvatore Pollicino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung CancerGerald S Falchook, Nelson G Ordóñez, Christel C Bastida, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2015
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profilingSai-Hong Ignatius Ou, Zachary R Chalmers, Michele C Azada, et al.
Oncoimmunology|February 6, 2018
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapiesAaron M Goodman, Shumei Kato, Philip R Cohen, et al.
Molecular Cancer Therapeutics|August 25, 2017
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M Goodman, Shumei Kato, Lyudmila Bazhenova, et al.
Journal of Natural Products|August 2, 2007
Prismatomerin, a new iridoid from Prismatomeris tetrandra. Structure elucidation, determination of absolute configuration, and cytotoxicityKarsten Krohn, Dietmar Gehle, Sujit Kumar Dey, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Oncoscience|August 5, 2016
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsJennifer J Wheler, Johnique T Atkins, Filip Janku, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Journal of the National Cancer Institute|November 14, 2015
Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibVictor Wong, Dean Pavlick, Tim Brennan, et al.
Pageof 17